Lymphotactin expression by engineered myeloma cells drives tumor regression: Mediation by CD4+ and CD8+ T cells and neutrophils expressing XCR1 receptor

Journal of Immunology

Volumn 167, Issue 1, 2001, Pages 57-65

  Cairns, C M ^a   Gordon, J R ^a   Li, F ^a   Baca Estrada, M E ^a   Moyana, T ^a   Xiang, J ^a  

^a Saskatoon Cancer Center   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR XCR1; LYMPHOTACTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CHEMOTAXIS; FEMALE; MOUSE; MYELOMA CELL; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REGRESSION;

EID: 0035399613     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.1.57     Document Type: Article

References (44)

1. Mechanisms of rejection induced by tumor cell-targeted gene transfer of IL-2, IL-4, IL-7, tumor necrosis factor or interferon γ
2. Mouse myeloma cell line secreting bifunctional fusion protein RM4/IFN elicits antitumor CD8 MHC class I-restricted T cells that are cytolytic in vitro and tumoricidal in vivo
3. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with IL-2, IL-4, IL-6, IL-7, IL-10, TNF, GMCSF and IFN gene or admixed with conventional adjuvants
4. Characterization of antitumor immunity derived from the inoculation of myeloma cells secreting the fusion protein RM4/IFN-r
5. Co-stimulation of tumor-reactive CD4 and CD8 T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma
6. Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12 but not B7-1 transfected tumor cells
7. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
8. Lymphocyte homing and homeostasis
9. C-C chemokines, but not the C-X-C chemokines IL-8 and interferon γ inducible protein- 10, stimulate transendothelial chemotaxis of T lymphocytes
10. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines
11. Chemokines, inflammation and the immune system
12. Properties of the novel proinflammatory supergene 'intercrine' cytokine family
13. IP-10, a C-X-C chemokine, elicits a potent thymus-dependent antitumor response in vivo
14. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo
15. Chemokine gene transfer into tumor cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration
16. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: Role of immune cell subpopulations
17. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: Perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor
18. Strong cytotoxic T lymphocyte responses to a macrophage infiltration protein 1α-expressing tumor: Linkage between inflammation and specific immunity
19. Molecular cloning and functional characterization of human lymphotactin
20. Lymphotactin is produced by NK cells and attracts both NK cells and T cells in vivo
21. Molecular cloning of mXCR1, the murine SCM-1/lymphotactin receptor
22. Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1
23. Preparation and functional analysis of human nonlymphoid cells
24. Production and functional characterization of recombinant bovine interleukin-8 as a neutrophil-activator and specific chemoattractant in vitro and in vivo
25. Construction and characterization of a high-affinity chimeric anti-colorectal carcinoma antibody ccM4
26. Chemokine gene expression transfection into tumor cells reduced tumorigenicity in nude mice in association with neutrophil infiltration
27. Cytotoxic CD4 T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-γ are cytolytic in vitro and tumoricidal in vivo
28. Neutralization of macrophage inflammatory protein-2 attenuates neutrophil recruitment and bacterial clearance in murine Klebsiella pneumoniae
29. Macrophage inflammatory proteins 1 and 2: Members of a novel superfamily of cytokines
30. + T cells
31. Combined chemokine and cytokine gene transfer enhances antitumor immunity
32. Role of neutrophils and CD4 T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene
33. Granulocyte colony-stimulating factor gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo
34. Regression of an established tumor genetically modified to release GM-CSF requires granulocyte-T cell cooperation and T cell-induced interferon γ
35. Chemokine gene transfection into tumor cells reduced tumorigenicity in nude mice in association with neutrophil infiltration
36. IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration
37. IL-1β or tumor necrosis factor α stimulate release of three NAP-1/IL-8-released neutrophil chemotactic proteins in human dermal fibroblasts
38. CD8 T cells infiltrated within cancer cell nest as a prognostic factor in human colorectal cancer
39. A critical role for a peritumoral stromal reaction in the induction of T-cell migration responsible for IL-12-induced tumor regression
40. Tumor localization of adoptively transferred indium-111 labelled tumor infiltrating lymphocytes in patients with metastatic melanoma
41. Localization of indium-111 labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy
42. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficiency
43. Intratumoral vaccination of adenovirus expressing fusion protein RM4/TNF induces significant tumor regression
44. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer